Address
Form of workTexas Biomed is partnering with Lindauer Global Executive Search. Please reach out directly to:Terri Rutter, Assistant Vice President, trutter@lindauerglobal.com orKhushboo Rami-Patel, Consultant, kramipatel@lindauerglobal.comto express your interest in applying for this opportunity or to make a nomination.
The Opportunity:
The Texas Biomedical Research Institute (Texas Biomed) is one of the nation's leading nonprofit, independent research institutes, dedicated to enhancing health and quality of life through transformational biomedical research. Its mission is to pioneer and share scientific breakthroughs that protect you, your families, and the global community from the threat of infectious diseases. The Institute thrives on learning and innovation, bringing together discovery-based science and applied research with an entrepreneurial spirit that produces high-quality findings applicable to a broad range of stakeholders. Its combined research expertise and range of facilities and resources make it a unique enterprise, found nowhere else in North America. The Institute is in an exciting phase of strategic growth, engaging local, regional, national, and international partners in academia, the private sector and government.
Texas Biomed seeks an accomplished development leader with successful fundraising experience in health sciences and/or academic medicine to serve as its Vice President of Development (VP). Reporting to the President and CEO, Larry Schlesinger, M.D., a visionary and proven leader who is highly supportive of fundraising, the VP will set the long-term vision and direction for the development program and team. As a seasoned leader, the VP will bring a collaborative and mentorship-based approach to motivate and coach a team of four highly ambitious and hardworking professionals. The VP will join the Institute during the silent phase of an ambitious multimillion-dollar comprehensive campaign, A Scientific Revolution, and will be critical to ensuring its success through strategic implementation and execution. They will develop new outreach and fundraising strategies while continuing to advance relationships with existing prospects and donors, including Trustees, in order to increase engagement and philanthropic contributions to Texas Biomed.
With an entrepreneurial and creative approach, the VP will bring professional expertise and best practices to the Institute. A successful candidate will be a highly motivated, intellectually curious, and broad thinker with a proven track record in securing major and principal gifts. As a visible member of the internal and external community, the VP must have professional acumen and strong communication skills to successfully engage senior leadership, scientists and faculty, and various groups and constituencies. The ability to collaborate and build relationships across the Institute, within the San Antonio community, and across the state and nationally to successfully build and grow Texas Biomed's fundraising program to its greatest potential is fundamental.
Texas Biomedical Research Institute
The Texas Biomedical Research Institute is a national leader among nonprofit, independent research institutes (within the Association of Independent Research Institutes) working exclusively on infectious diseases threatening our future. Vulnerable populations to infection are a particular focus, including those with chronic inflammatory diseases, diabetes, cardiovascular disease, cancer, and the elderly. Located on a 200-acre campus in San Antonio, Texas, Texas Biomed partners with hundreds of researchers and organizations around the world, targeting advances in the fight against infectious diseases, including AIDS, TB, hepatitis, malaria, Ebola, zika, and parasitic infections, as well as new and emerging threats, such as COVID-19. Founded in 1941, the Institute enjoys tremendous support from city leaders, public and private sector partners and the community. It has also benefited from a diverse range of revenue sources.
Texas Biomed is home to the only privately owned and operated maximum containment Biosafety Level (BSL)-4 facility, which is paired with six BSL3 facilities with a range of technologies including PET-CT imaging, and one of only seven National Primate Research Centers (NPRCs) in the United States funded by the NIH.
The Southwest National Primate Research Center provides specialized facilities and expertise in research with non-human primates to investigators from around the United States and other countries. It maintains nearly 3,000 non-human primates.
Texas Biomed is the nation's only independent research institute with a fully integrated primate research center and the highest-level biosafety laboratories on one campus.
As an independent, nonprofit research institute, Texas Biomedical Research Institute has the flexibility to work with partners worldwide from federal agencies, such as the National Institutes of Health and Department of Defense, to independent researchers to biotechnology and pharmaceutical companies.
Texas Biomed utilizes a team science approach to provide the right expertise, unique resources, and a business model with flexibility, reliability, and speed in mind to generate discoveries that ultimately benefit human health. Current local partnerships include the San Antonio Partnership for Precision Therapeutics and the Vaccine Development Center, which both aim to bring together experts and resources from Texas Biomed, Southwest Research Institute, the University of Texas at San Antonio, and UTHealth to create research opportunities in the areas of precision medicine and vaccine development. Texas Biomed also works closely with UTHealth's Barshop Center for Longevity and Aging and maintains strong relationships with biotechnology companies throughout the city and state.
The researchers at Texas Biomed are working together in three critical programmatic areas of discovery:
Host-Pathogen Interactions (HPI)
The HPI program concentrates on the basic biology of infection in humans and animals and the development of disease. Scientists focus on how an infectious agent such as a parasite, bacteria, virus, or fungus can enter our bodies and/or cells and cause illness. Scientists at Texas Biomed are, for example, determining how Ebola or Mycobacterium tuberculosis can infect cells and cause illness or how HIV can subvert our immune system to persist in our bodies. Disease Intervention and Prevention (DIP)
The DIP program aids in the development of diagnostics, treatments, and vaccines to prevent disease and reduce the severity, if not cure, disease and infection. Scientists at Texas Biomed are, for example, working to develop new vaccines for HIV and Ebola, new drugs for malaria and schistosomiasis, and new diagnostics for tuberculosis.
Population Health (PH)
The PH program aims to identify correlates of disease susceptibility or resistance to infectious diseases on a population level. Examples at Texas Biomed include studying how genetic variation impacts neurological disorders, heart disease, diabetes, and infection.
Vision for Change - 10-year Strategic Plan
In December 2019, Texas Biomed launched a 10-year strategic plan, the Vision for Change. This bold initiative arose from the realization that by 2050 infectious diseases are projected to be the number one killer globally, at a cost of $100 trillion - and that Texas Biomed is well placed to respond.
The Vision for Change is rapidly increasing recognition of the need for the Institution's unparalleled research, new funding, and technological innovations that will help advance the groundbreaking science for which Texas Biomed has become known. As a world leader in infectious disease research and building on the Institution's reputation as a "best place to work," the plan is catapulting the Institution ahead on six trajectories: science and technology, organizational structure, training and career development, facilities and infrastructure, culture, and business development.
Development Overview
Texas Biomed's Campaign - A Scientific Revolution:
With the ability to spread faster than ever before, infectious disease threats are growing, especially in the most vulnerable populations. Texas Biomed plans to double its scientists and resources in the coming decade through an ambitious $350 million comprehensive campaign, A Scientific Revolution, to meet this challenge, save lives, and be the world leader in infectious disease.
The Campaign will fund three initiatives.
• People - recruitment of teams of top scientists with specific expertise in infection and dedicated to collaborative scientific approaches to the challenges of infectious diseases, inflammation, and immunity.
• Programs - designing and funding the support systems needed to ensure a best practices organization, training of the next generation of biomedical researchers, and a creative science and related business environment.
• Places - redeveloping the Texas Biomed campus to increase the effectiveness of our research and the collaboration of our scientists.
Significant progress on the campaign has been made over the past five years, including about $100 million invested in enhancements to the Institute's campus. These include a combination of new facilities (such as the two new recently completed additions to our Animal Care Complex) and significant renovations to existing campus spaces leading to increased capabilities, added capacity, and efficiencies. One of the noteworthy investments included the addition of a new 7,500 square feet BSL3 laboratory with imaging capabilities, which was critical in the work we performed to accelerate FDA approval of COVID-19 vaccines and therapies.
During this same time period, the Institute has made progress in other elements of its strategic plan, including hiring talented faculty and staff (employee count has grown from around 360 to about 450), programmatic enhancements (as one example, increasing our educational programming ranging from K-12 to post-doc programs), adding capabilities (new state-of-the-art scientific equipment and information technology resources), and enhancements for our employees (new wellness center, on-site medical clinic, food offerings, etc.) yielding first-quartile employee engagement survey scores. Also, during this period, the Institute's annual grant and contract revenues have grown from around $35 million annually to over $70 million, driven by our highly productive faculty and increased business relationships with the addition of a dedicated business development team in 2020.
Funding for these enhancements has come from a variety of sources, including issuing public debt, selling underutilized real estate assets, federal grant support, local government assistance, and - of course - philanthropy. The next phase of the campaign will focus on securing the necessary resources to provide funding for bringing new critical facilities online and further building out the campus to facilitate the growth envisioned in the strategic plan. Philanthropy will necessarily be called on for heavy lifting to support these plans but will certainly be supplemented by other sources, including another planned debt financing later this year. The priorities for the capital campaign have been finely tuned, including marketing materials and a strong, collaborative Corporate Communications team.
Other Affiliations and Campaigns:
Texas Biomed retains a strong volunteer fundraising support base through longstanding voluntary support groups such as the Texas Biomedical Forum (a supporting group of 600 women who raise resources for pilot studies), the Founder's Council (a group of 350 young community business and social leaders who raise awareness of Texas Biomed's research programs and raise funds for small equipment grants), and The Argyle (a private club comprised of 1400 members who make annual donations together totaling $1.2 million). The support of the philanthropic community led to a successful campaign in 2014 raising over $35 million.
Leadership
Dr. Larry Schlesinger
President/CEO
Larry S. Schlesinger, M.D., is an internationally recognized authority on infectious diseases with a particular interest in tuberculosis and lung biology. He took the reins of leadership as President/CEO of Texas Biomed in 2017 and has led a transformational strategic planning process that is currently being implemented.
Since coming to San Antonio, Dr. Schlesinger has made a huge impact on the San Antonio biomedical research community, particularly building stronger relationships and innovative partnerships with UT Health San Antonio, Southwest Research Institute, the University of Texas at San Antonio, other colleges and universities in the region, and the private sector biomedical landscape. He serves on the boards of Biomed SA and the SA Medical Foundation and has spoken in several citywide venues discussing the virtues of working together to achieve great things.
Dr. Schlesinger also serves as a Professor at Texas Biomed and is Principal Investigator (PI) of several ongoing research grants. He serves as PI for the Southwest National Primate Research Center Base Grant. In 2018, Dr. Schlesinger was named a Healthcare Hero by the San Antonio Business Journal in the area of Outstanding Medical Researcher. In 2021, he was awarded Word Affairs Council of San Antonio International Citizen of the Year.
Dr. Schlesinger earned a B.A. in Biology from Cornell University and M.D. from Rutgers Medical School. He completed his residency in internal medicine at the University of Michigan and clinical and research fellowships in infectious diseases at UCLA. In 1991, he joined the faculty at the University of Iowa, where he served as Fellowship Director for the Division of Infectious Diseases and Associate Chair of the Department of Medicine. In 2002, he moved to the Ohio State University, where he served as Director of the Division of Infectious Diseases, Department of Internal Medicine, until 2011, when he became first chair of Microbial Infection and Immunity. He also founded the university-wide Center for Microbial Interface Biology (now the Infectious Diseases Research Institute).
Dr. Schlesinger is a leading physician scientist whose studies focus on the pathogenesis of tuberculosis and other airborne infectious agents that subvert lung immune mechanisms. His discoveries have...
The Opportunity:
The Texas Biomedical Research Institute (Texas Biomed) is one of the nation's leading nonprofit, independent research institutes, dedicated to enhancing health and quality of life through transformational biomedical research. Its mission is to pioneer and share scientific breakthroughs that protect you, your families, and the global community from the threat of infectious diseases. The Institute thrives on learning and innovation, bringing together discovery-based science and applied research with an entrepreneurial spirit that produces high-quality findings applicable to a broad range of stakeholders. Its combined research expertise and range of facilities and resources make it a unique enterprise, found nowhere else in North America. The Institute is in an exciting phase of strategic growth, engaging local, regional, national, and international partners in academia, the private sector and government.
Texas Biomed seeks an accomplished development leader with successful fundraising experience in health sciences and/or academic medicine to serve as its Vice President of Development (VP). Reporting to the President and CEO, Larry Schlesinger, M.D., a visionary and proven leader who is highly supportive of fundraising, the VP will set the long-term vision and direction for the development program and team. As a seasoned leader, the VP will bring a collaborative and mentorship-based approach to motivate and coach a team of four highly ambitious and hardworking professionals. The VP will join the Institute during the silent phase of an ambitious multimillion-dollar comprehensive campaign, A Scientific Revolution, and will be critical to ensuring its success through strategic implementation and execution. They will develop new outreach and fundraising strategies while continuing to advance relationships with existing prospects and donors, including Trustees, in order to increase engagement and philanthropic contributions to Texas Biomed.
With an entrepreneurial and creative approach, the VP will bring professional expertise and best practices to the Institute. A successful candidate will be a highly motivated, intellectually curious, and broad thinker with a proven track record in securing major and principal gifts. As a visible member of the internal and external community, the VP must have professional acumen and strong communication skills to successfully engage senior leadership, scientists and faculty, and various groups and constituencies. The ability to collaborate and build relationships across the Institute, within the San Antonio community, and across the state and nationally to successfully build and grow Texas Biomed's fundraising program to its greatest potential is fundamental.
Texas Biomedical Research Institute
The Texas Biomedical Research Institute is a national leader among nonprofit, independent research institutes (within the Association of Independent Research Institutes) working exclusively on infectious diseases threatening our future. Vulnerable populations to infection are a particular focus, including those with chronic inflammatory diseases, diabetes, cardiovascular disease, cancer, and the elderly. Located on a 200-acre campus in San Antonio, Texas, Texas Biomed partners with hundreds of researchers and organizations around the world, targeting advances in the fight against infectious diseases, including AIDS, TB, hepatitis, malaria, Ebola, zika, and parasitic infections, as well as new and emerging threats, such as COVID-19. Founded in 1941, the Institute enjoys tremendous support from city leaders, public and private sector partners and the community. It has also benefited from a diverse range of revenue sources.
Texas Biomed is home to the only privately owned and operated maximum containment Biosafety Level (BSL)-4 facility, which is paired with six BSL3 facilities with a range of technologies including PET-CT imaging, and one of only seven National Primate Research Centers (NPRCs) in the United States funded by the NIH.
The Southwest National Primate Research Center provides specialized facilities and expertise in research with non-human primates to investigators from around the United States and other countries. It maintains nearly 3,000 non-human primates.
Texas Biomed is the nation's only independent research institute with a fully integrated primate research center and the highest-level biosafety laboratories on one campus.
As an independent, nonprofit research institute, Texas Biomedical Research Institute has the flexibility to work with partners worldwide from federal agencies, such as the National Institutes of Health and Department of Defense, to independent researchers to biotechnology and pharmaceutical companies.
Texas Biomed utilizes a team science approach to provide the right expertise, unique resources, and a business model with flexibility, reliability, and speed in mind to generate discoveries that ultimately benefit human health. Current local partnerships include the San Antonio Partnership for Precision Therapeutics and the Vaccine Development Center, which both aim to bring together experts and resources from Texas Biomed, Southwest Research Institute, the University of Texas at San Antonio, and UTHealth to create research opportunities in the areas of precision medicine and vaccine development. Texas Biomed also works closely with UTHealth's Barshop Center for Longevity and Aging and maintains strong relationships with biotechnology companies throughout the city and state.
The researchers at Texas Biomed are working together in three critical programmatic areas of discovery:
Host-Pathogen Interactions (HPI)
The HPI program concentrates on the basic biology of infection in humans and animals and the development of disease. Scientists focus on how an infectious agent such as a parasite, bacteria, virus, or fungus can enter our bodies and/or cells and cause illness. Scientists at Texas Biomed are, for example, determining how Ebola or Mycobacterium tuberculosis can infect cells and cause illness or how HIV can subvert our immune system to persist in our bodies. Disease Intervention and Prevention (DIP)
The DIP program aids in the development of diagnostics, treatments, and vaccines to prevent disease and reduce the severity, if not cure, disease and infection. Scientists at Texas Biomed are, for example, working to develop new vaccines for HIV and Ebola, new drugs for malaria and schistosomiasis, and new diagnostics for tuberculosis.
Population Health (PH)
The PH program aims to identify correlates of disease susceptibility or resistance to infectious diseases on a population level. Examples at Texas Biomed include studying how genetic variation impacts neurological disorders, heart disease, diabetes, and infection.
Vision for Change - 10-year Strategic Plan
In December 2019, Texas Biomed launched a 10-year strategic plan, the Vision for Change. This bold initiative arose from the realization that by 2050 infectious diseases are projected to be the number one killer globally, at a cost of $100 trillion - and that Texas Biomed is well placed to respond.
The Vision for Change is rapidly increasing recognition of the need for the Institution's unparalleled research, new funding, and technological innovations that will help advance the groundbreaking science for which Texas Biomed has become known. As a world leader in infectious disease research and building on the Institution's reputation as a "best place to work," the plan is catapulting the Institution ahead on six trajectories: science and technology, organizational structure, training and career development, facilities and infrastructure, culture, and business development.
Development Overview
Texas Biomed's Campaign - A Scientific Revolution:
With the ability to spread faster than ever before, infectious disease threats are growing, especially in the most vulnerable populations. Texas Biomed plans to double its scientists and resources in the coming decade through an ambitious $350 million comprehensive campaign, A Scientific Revolution, to meet this challenge, save lives, and be the world leader in infectious disease.
The Campaign will fund three initiatives.
• People - recruitment of teams of top scientists with specific expertise in infection and dedicated to collaborative scientific approaches to the challenges of infectious diseases, inflammation, and immunity.
• Programs - designing and funding the support systems needed to ensure a best practices organization, training of the next generation of biomedical researchers, and a creative science and related business environment.
• Places - redeveloping the Texas Biomed campus to increase the effectiveness of our research and the collaboration of our scientists.
Significant progress on the campaign has been made over the past five years, including about $100 million invested in enhancements to the Institute's campus. These include a combination of new facilities (such as the two new recently completed additions to our Animal Care Complex) and significant renovations to existing campus spaces leading to increased capabilities, added capacity, and efficiencies. One of the noteworthy investments included the addition of a new 7,500 square feet BSL3 laboratory with imaging capabilities, which was critical in the work we performed to accelerate FDA approval of COVID-19 vaccines and therapies.
During this same time period, the Institute has made progress in other elements of its strategic plan, including hiring talented faculty and staff (employee count has grown from around 360 to about 450), programmatic enhancements (as one example, increasing our educational programming ranging from K-12 to post-doc programs), adding capabilities (new state-of-the-art scientific equipment and information technology resources), and enhancements for our employees (new wellness center, on-site medical clinic, food offerings, etc.) yielding first-quartile employee engagement survey scores. Also, during this period, the Institute's annual grant and contract revenues have grown from around $35 million annually to over $70 million, driven by our highly productive faculty and increased business relationships with the addition of a dedicated business development team in 2020.
Funding for these enhancements has come from a variety of sources, including issuing public debt, selling underutilized real estate assets, federal grant support, local government assistance, and - of course - philanthropy. The next phase of the campaign will focus on securing the necessary resources to provide funding for bringing new critical facilities online and further building out the campus to facilitate the growth envisioned in the strategic plan. Philanthropy will necessarily be called on for heavy lifting to support these plans but will certainly be supplemented by other sources, including another planned debt financing later this year. The priorities for the capital campaign have been finely tuned, including marketing materials and a strong, collaborative Corporate Communications team.
Other Affiliations and Campaigns:
Texas Biomed retains a strong volunteer fundraising support base through longstanding voluntary support groups such as the Texas Biomedical Forum (a supporting group of 600 women who raise resources for pilot studies), the Founder's Council (a group of 350 young community business and social leaders who raise awareness of Texas Biomed's research programs and raise funds for small equipment grants), and The Argyle (a private club comprised of 1400 members who make annual donations together totaling $1.2 million). The support of the philanthropic community led to a successful campaign in 2014 raising over $35 million.
Leadership
Dr. Larry Schlesinger
President/CEO
Larry S. Schlesinger, M.D., is an internationally recognized authority on infectious diseases with a particular interest in tuberculosis and lung biology. He took the reins of leadership as President/CEO of Texas Biomed in 2017 and has led a transformational strategic planning process that is currently being implemented.
Since coming to San Antonio, Dr. Schlesinger has made a huge impact on the San Antonio biomedical research community, particularly building stronger relationships and innovative partnerships with UT Health San Antonio, Southwest Research Institute, the University of Texas at San Antonio, other colleges and universities in the region, and the private sector biomedical landscape. He serves on the boards of Biomed SA and the SA Medical Foundation and has spoken in several citywide venues discussing the virtues of working together to achieve great things.
Dr. Schlesinger also serves as a Professor at Texas Biomed and is Principal Investigator (PI) of several ongoing research grants. He serves as PI for the Southwest National Primate Research Center Base Grant. In 2018, Dr. Schlesinger was named a Healthcare Hero by the San Antonio Business Journal in the area of Outstanding Medical Researcher. In 2021, he was awarded Word Affairs Council of San Antonio International Citizen of the Year.
Dr. Schlesinger earned a B.A. in Biology from Cornell University and M.D. from Rutgers Medical School. He completed his residency in internal medicine at the University of Michigan and clinical and research fellowships in infectious diseases at UCLA. In 1991, he joined the faculty at the University of Iowa, where he served as Fellowship Director for the Division of Infectious Diseases and Associate Chair of the Department of Medicine. In 2002, he moved to the Ohio State University, where he served as Director of the Division of Infectious Diseases, Department of Internal Medicine, until 2011, when he became first chair of Microbial Infection and Immunity. He also founded the university-wide Center for Microbial Interface Biology (now the Infectious Diseases Research Institute).
Dr. Schlesinger is a leading physician scientist whose studies focus on the pathogenesis of tuberculosis and other airborne infectious agents that subvert lung immune mechanisms. His discoveries have...
